Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokers have set a 1 year consensus target price of $24.00 for the company and are predicting that the company will post ($0.55) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aeglea Bio Therapeutics an industry rank of 109 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research raised shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 price target for the company in a research report on Friday, November 10th.
Aeglea Bio Therapeutics (NASDAQ AGLE) traded down $0.02 during midday trading on Friday, hitting $4.99. 78,400 shares of the stock traded hands, compared to its average volume of 66,386. Aeglea Bio Therapeutics has a 12-month low of $2.81 and a 12-month high of $8.14.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.48) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.07. Aeglea Bio Therapeutics had a negative net margin of 527.99% and a negative return on equity of 44.05%. The firm had revenue of $1.26 million during the quarter. sell-side analysts expect that Aeglea Bio Therapeutics will post -1.97 earnings per share for the current fiscal year.
In related news, CFO Charles N. York II acquired 25,959 shares of the business’s stock in a transaction that occurred on Tuesday, December 5th. The stock was bought at an average cost of $4.48 per share, for a total transaction of $116,296.32. Following the purchase, the chief financial officer now owns 10,828 shares in the company, valued at approximately $48,509.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Charles N. York II acquired 6,500 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were bought at an average price of $4.59 per share, with a total value of $29,835.00. Following the completion of the purchase, the chief financial officer now owns 10,828 shares in the company, valued at approximately $49,700.52. The disclosure for this purchase can be found here. Insiders have bought a total of 57,691 shares of company stock valued at $269,483 in the last ninety days. Insiders own 27.00% of the company’s stock.
Several large investors have recently made changes to their positions in AGLE. Renaissance Technologies LLC bought a new position in shares of Aeglea Bio Therapeutics during the 1st quarter valued at approximately $270,000. Vanguard Group Inc. grew its stake in shares of Aeglea Bio Therapeutics by 9.4% during the 2nd quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock valued at $579,000 after acquiring an additional 12,966 shares during the period. Finally, Susquehanna International Group LLP bought a new position in shares of Aeglea Bio Therapeutics during the 2nd quarter valued at approximately $653,000. Institutional investors own 46.89% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Set $24.00 Target Price for Aeglea Bio Therapeutics Inc (AGLE)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/11/zacks-brokerages-set-24-00-target-price-for-aeglea-bio-therapeutics-inc-agle.html.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.